Posted by Michael Wonder on 13 Apr 2017
Clinuvel reaches agreement on German Scenesse pricing through AMNOG Arbitration Board
12 April 2017 - Clinuvel today announced that it had reached agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband or GKV-SV) for the treatment of erythropoietic protoporphyria patients with Clinuvel's drug Scenesse (afamelanotide).
Clinuvel had been in mandatory ‘negotiation’ with GKV-SV since August 2016. Under the German Pharmaceuticals Market Reorganisation Act (AMNOG) a pricing agreement was reached after an Arbitration Board was called.
The outcome of the Arbitration Board is legally binding for all state insurers (‘Krankenkassen’) in Germany.
